A Resource Guide to Investing in Biotechnology
Directory - Encyclopedia - Stock Index - Drugs  

Biotech100 Stock Index

Elexis Inc.

About Elexis

Exelixis is a genomics-based drug discovery company focused on the discovery and development of potential new drug therapies, specifically for cancer and other proliferative diseases.

Elexis' most advanced clinical program is XL119 (becatecarin), an anticancer compound as a potential treatment for patients with bile duct tumors. that was in-licensed from Bristol-Myers Squibb in 2001.

XL784 is the first small molecule compound developed from their proprietary drug discovery platform for which they have filed an investigational new drug application (IND). XL784 has completed a Phase 1 clinical trial and has demonstrated potential utility in renal disease.


Pipeline for Exelixis



More on Exelixis

Home Page

Key Statistics for Exelixis

Basic Chart for Exelixis

Analyst Opinion

Analysts Estimates


Biotech100 Index
What are the Requirements to be listed in the Biotech100 Index?
See the Biotech100 List

Sponsored Links

Clinical Trials
What is a Clinical Trial?
Phase I ,-- Phase II, -- PhaseIII
What is Randomized Control?
 What is a Double Blind Experiment?
What is the role of the FDA?


Key Biotech Terms


Biotech Resources


Investing in Stocks
Small Cap Stocks
Stocks and Bonds
Biotech100 Index

Careers and Employment
Biotechnology and Pharmaceutical
What are the Fastest Growing Careers?




Copyright 2005 BIOTECH100.COM. All rights reserved.